GlassScriptPhysician profile
Lindsay Ketzner
NPI 1366805509
$4,848.64
in general payments reported to CMS, 2019-2025
27 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $392 · 2021: $1,192 · 2022: $759 · 2023: $668 · 2024: $1,035 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.16 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $826.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $800.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $753.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $752.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $364.20 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $215.92 | 2020-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $117.15 | 2020-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $116.13 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $96.99 | 2019-2022 | |
| Pfizer INC. | $89.50 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $88.20 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.87 | 2021 | |
| Allergan, INC. | $66.18 | 2020-2021 | |
| Esperion Therapeutics, INC. | $57.29 | 2020-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $57.11 | 2024-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $52.53 | 2025 | Auvelity |
| Shield Therapeutics INC | $42.58 | 2024 | |
| Dexcom, INC. | $37.23 | 2024-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $35.97 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.47 | 2022 | |
| Mylan Specialty L.P. | $32.47 | 2022-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $26.28 | 2021 | |
| Currax Pharmaceuticals LLC | $25.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2025 | Jardiance |
| Viatris Specialty LLC | $19.73 | 2025 | Yupelri |
| Boston Scientific Corporation | $19.62 | 2019 | |
| Sanofi Pasteur INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Ketzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.